/ Active, not recruitingPhase 1 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ103 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.
/ Active, not recruitingPhase 1 A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ101 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.
100 Clinical Results associated with Xinyao Biology (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Xinyao Biology (Shanghai) Co., Ltd.
100 Deals associated with Xinyao Biology (Shanghai) Co., Ltd.
100 Translational Medicine associated with Xinyao Biology (Shanghai) Co., Ltd.